Morningstar generic-pharmaceuticals analyst Brian Laegeler discusses the outlook for generic biologics in the U.S. given a strong branded-drug lobby and complex manufacturing processes.
Contract research organization Parexel is exploiting its global footprint to rapidly enroll patients in drug studies.
Associate director for health-care analysis Alex Morozov on the uncertainty-overhang relief, biggest winners, and best values in post-reform health care.
Big pharmaceutical companies are getting lean in an attempt to boost profitability before they lose patent protection on several important drugs, says Morningstar's Damien Conover.
©2012 Morningstar Advisor. All right reserved.